2011: keep calm and carry on
This article was originally published in Scrip
Executive Summary
With all the commotion surrounding looming patent expiries, uncertainty still around US healthcare reforms, and the impact of economic austerity measures, it is not surprising that the pharmaceutical and biopharmaceutical sectors have lost some of their allure to generalist investors. However, with more than 7,000 delegates at this week's JP Morgan Healthcare conference, the industry's annual get together in San Francisco, many companies are in a much healthier position than may have been supposed.